Business Context and Reporting Period
Company: Zhengye Biotechnology Holding Ltd (Ticker: ZYBT)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: A Cayman Islands holding company conducting operations through PRC subsidiaries, primarily Jilin Zhengye. The company focuses on the research, development, manufacturing, and sales of veterinary vaccines, with a heavy emphasis on swine vaccines. Products are sold domestically in China and exported to Vietnam, Pakistan, and Egypt.
Recent Corporate Action: Completed an Initial Public Offering (IPO) on January 8, 2025, listing on the Nasdaq Capital Market. A 4-for-1 forward stock split was executed on June 6, 2024.
Key Financial Metrics (Fiscal Year 2024)
| Metric | 2024 (RMB '000) | 2024 (USD '000) | 2023 (RMB '000) | 2022 (RMB '000) |
|---|---|---|---|---|
| Net Revenue | 186,356 | 25,531 | 211,651 | 260,269 |
| Gross Profit | 91,295 | 12,508 | 117,508 | 147,879 |
| Gross Margin | 49.0% | 49.0% | 55.5% | 56.8% |
| Operating Income | 16,439 | 2,252 | 44,986 | 65,834 |
| Net Income | 13,470 | 1,846 | 37,509 | 55,742 |
| Net Income Attributable to Shareholders | 11,311 | 1,550 | 31,457 | 46,735 |
| Operating Cash Flow | 41,046 | 5,624 | 48,184 | 17,335 |
| Total Debt (Bank Loans) | 86,433 | 11,842 | 89,850 | N/A |
| Cash and Restricted Cash | 18,606 | 2,549 | 27,186 | 9,746 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 12.0% year-over-year (YoY) to RMB186.4 million. This was primarily driven by a strategic realignment to reduce customer concentration, resulting in reduced sales of swine vaccines to the largest customer (Muyuan Foods Co., Ltd.), whose share of revenue dropped from 52.1% in 2023 to 44.6% in 2024.
- Margin Compression: Gross margin declined from 55.5% in 2023 to 49.0% in 2024 due to lower sales prices and unchanged fixed costs.
- Profitability Drop: Net income attributable to shareholders fell 64.1% YoY to RMB11.3 million, reflecting the revenue decline and increased operating expenses.
- Operating Expenses: Total operating expenses increased slightly to RMB74.9 million (from RMB72.5 million in 2023), driven by higher sales and marketing costs and R&D expenses, partially offset by a reversal of credit losses.
- Customer Concentration: While still high, reliance on the top customer decreased. Muyuan Foods accounted for 44.6% of 2024 revenue compared to 52.1% in 2023 and 74.5% in 2022.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy
- Product Diversification: The company aims to expand beyond swine vaccines into poultry and companion animal vaccines (e.g., feline and canine vaccines). Several new products are in clinical trials or regulatory review.
- Use of Proceeds: Net IPO proceeds of approximately $6.0 million are intended for R&D projects, specifically for feline and rabies vaccines, and general corporate purposes.
- Market Expansion: Plans to expand distribution networks in Southeast Asia (Thailand, Philippines) and specific Chinese cities.
Material Risks
- Regulatory Risks (China): Significant risks related to PRC laws, including the Cybersecurity Review Measures, Anti-Monopoly Law, and the Overseas Listing Trial Measures. Changes in these regulations could disrupt operations or delist the company.
- PCAOB Inspection: Risk of delisting under the Holding Foreign Companies Accountable Act (HFCA Act) if the PCAOB cannot inspect the company's auditor (WWC, P.C.) for two consecutive years, though the auditor was last inspected in 2023.
- Customer Concentration: High dependence on a single customer (Muyuan Foods) remains a critical risk; any loss of this customer would materially impact revenue.
- Internal Controls: Management identified a material weakness in internal control over financial reporting as of December 31, 2024, due to a lack of accounting staff with appropriate U.S. GAAP knowledge. Remediation is in progress.
- Dividend Policy: The company does not intend to pay dividends in the foreseeable future, as earnings are needed for expansion.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the relationship with Muyuan Foods Co., Ltd. and the success of diversification efforts to reduce reliance below 45%.
- Internal Control Remediation: Monitor the progress of hiring qualified accounting personnel and implementing U.S. GAAP training to address the material weakness in internal controls.
- Regulatory Compliance: Confirm ongoing compliance with PRC overseas listing filing requirements (CSRC) and cybersecurity regulations to avoid operational disruption.
- R&D Pipeline: Track the regulatory approval status of new companion animal vaccines (feline and canine) and mRNA vaccine projects to assess future revenue growth drivers.
- Debt Maturity: Review the repayment schedule for outstanding bank loans (RMB86.4 million), noting that RMB81.6 million is due within one year.